undamentalytics Newsletter
Sign in

Inmed Pharmaceuticals Inc. revenue

Inmed Pharmaceuticals Inc.'s revenue was $4.9m in fiscal 2025, up 7.5% on the year before. Since fiscal 2021 ($1.9m) it has grown at a compound 26.9% a year. Over the last twelve months it was $4.5m.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Jun 20212022Jun 20222023Jun 20232024Jun 20242025Jun 2025LTMDec 2025
Revenue1,9041,0894,1364,5984,9434,507
Growth on the year before—−42.8%+279.6%+11.2%+7.5%—
Gross profit—5441,4031,1011,7071,340

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Inmed Pharmaceuticals Inc. $4.5m -6.7% 40.8%
Ensysce Biosciences, Inc. $4.5m -39.3% 14.6%
Ocugen, Inc. $4.6m -3.7% 26.3%
Entrada Therapeutics, Inc. $4.7m -94.1% —
Bolt Biotherapeutics, Inc. $4.7m 12.8% -11.5%
Curis Inc $4.3m -62.2% -25.0%

Compare with peers

Head to head: ENSC vs INMINM vs OCGNINM vs TRDA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Inmed Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Inmed Pharmaceuticals Inc.